Devonian Health Group Issues Securities in Interest Settlement Due to Debenture Holders and Grants Options
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc.…
Pharmaceuticals, Biotechnology and Life Sciences
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc.…
Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.
HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) (“Aptorum”) announced today, the appointment of Dr. Thomas Wai-yip Lee as Head of…
WOBURN, Mass.–(BUSINESS WIRE)–BioProcess Technology Consultants Inc. (BPTC) announced today the closing of its acquisition by BDO USA, LLP, one of…
First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer…
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating…
Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2018. Richard Toselli,…
In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine…
Company Presents Four Studies at American Association for Cancer Research (AACR) Annual Conference Preclinical Data for Lead Asset Repotrectinib Continue…